News

Bio Farma has selected Quantoom Biosciences’ Ntensify® RNA production platform to support Indonesia’s mRNA vaccine programs, after a first production run validated high-quality RNA output.

Anvisa has authorized the start of clinical trials for Brazil’s first mRNA vaccine, developed on Bio-Manguinhos/Fiocruz’s national mRNA platform and supported by Quantoom Biosciences’ Ntensify® technology for RNA production and purification.

Quantoom Biosciences and Inside Therapeutics announce a commercial collaboration connecting the Ntensify® micro and mini benchtop systems with the TAMARA LNP formulation platform, giving researchers a more integrated path from RNA production to formulated product.

Quantoom Biosciences partners with Labscoop to expand North American access to RNA solutions via the Labscoop Marketplace and Fulfillment by Labscoop (FBL).

Quantoom Biosciences and Enparis Bio (India) announce a strategic partnership to accelerate access to the N-Force platform across India's vaccine, biotech and life-science sectors.

Quantoom and Nucelion Therapeutics signed an MoU to explore a preferred RNA CDMO partnership in India, expanding N-Force platform access across human therapeutics and animal health.

Nivelles, Belgium / Kuala Lumpur, Malaysia — March 25, 2026 — Quantoom Biosciences, a full-stack RNA partner providing turnkey solutions for mRNA- and saRNA-based vaccines and therapeutics, today announced a distribution

Nivelles, Belgium — March 17, 2026 — Quantoom Biosciences today announced a new distribution partnership with Europa Biosite, a leading and fast-growing European life-science distributor. The agreement expands access to

Quantoom Biosciences and Skybioscienc to collaborate on South-Korean distribution for Ntensify® mano and Ntensify® micro Nivelles [Nivelles, Belgium] / [Incheon, South-Korea] — Mar 12, 2026 — Quantoom Biosciences, a full-stack RNA partner

Nivelles, Belgium, and Houston, Texas — February 9, 2026 Quantoom Biosciences, a leader in integrated RNA-LNP manufacturing technologies, today announced Soter Bio as its exclusive RNA Contract Development and Manufacturing

Cape Town, South Africa & Brussels, Belgium— December 12th, 2025 Afrigen Biologics and Quantoom Biosciences today announced the successful completion of a technical production run (800ml IVT) for an mRNA-based

Perth, Australia & Nivelles, Belgium – December 3, 2025 Quantoom Biosciences today announced the adoption of the Ntensify® mini platform by The University of Western Australia’s (UWA) RNA Innovation Foundry

Nivelles, Belgium — September 25, 2025 Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading institutions for cancer treatment, research, and education, and Quantoom Biosciences, a full-stack RNA

Medellín, Colombia and Nivelles, Belgium – June 23, 2025 VaxThera, a biotechnology company that produce vaccines and biologics, and Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines

Quantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions SAN DIEGO (June 3, 2025) TriLink

REDMOND, Wash., & NIVELLES, Belgium – May 15, 2025 Inventprise Inc., a clinical-stage vaccine invention company, announced today its selection of Quantoom Biosciences’ Ntensify midi system as the core technology

NIVELLES, Belgium – April 14, 2025 Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics, is proud to announce a research collaboration with the University of

Manchester, CT, USA & NIVELLES, Belgium – March 31, 2025 Quantoom Biosciences and DIANT Pharma Inc. are proud to announce a strategic collaboration to advance the supply chain for messenger

March 2025 At the end of February, CAPTIVATE-EU held its annual meeting in Barcelona! Scientists Youlia Serikova and Erica Pasini took a moment after the session to share their key

Pirbright, UK & Nivelles, Belgium – Thursday, March 13, 2025 The Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM), part of The Pirbright Institute, a world-leading center for the research

Wednesday, March 5, 2025 TechInvention Lifecare Pvt. Ltd. (TechInvention) is proud to announce a strategic collaboration with Belgium-based Quantoom Biosciences (Quantoom). The Memorandum of Understanding (MoU) was formally signed during

Cairo, Egypt – February 5, 2025 – Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding today, on the sidelines of the 2nd

Rio de Janeiro, Brazil – November 29, 2024 – During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation

ST Pharm, a leading technology-driven RNA CDMO, and Quantoom Biosciences (also referred as “Quantoom”), a specialized RNA technology platform developer, today announced an extended collaboration to accelerate the development and

DURHAM, North Carolina – Quantoom Biosciences S.A. (“Quantoom”), part of Univercells S.A., focused on mRNA production technologies for vaccines and therapeutics, and Tiamat Sciences, a plant-based platform and product life

Nivelles, Belgium – Quantoom Biosciences S.A. (“Quantoom”), a subsidiary of Univercells S.A., proudly announces the extension of the Ntensify® product line with the launch of Ntensify® mano, an mRNA kit

Quantoom Biosciences S.A. (“Quantoom”), part of Univercells S.A. is proud to announce its significant collaboration with the Institute of Technology on Immunobiologicals (Bio-Manguinhos/Fiocruz), Brazil’s leading public health institute and vaccine

The Ntensify® Midi System Sets the Stage for Equitable Vaccine Access Quantoom Biosciences S.A. (“Quantoom”), a Univercells company, proudly announces the implementation of its first Ntensify® Midi system for mRNA

Quantoom Biosciences (‘Quantoom’) is thrilled to announce a new collaboration with Stevanato Group, a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries,

Quantoom Biosciences S.A. (“Quantoom”), a Univercells company, is proud to unveil the latest addition to its offering: a service for DNA amplification for use in mRNA applications.

Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable and automated DNA synthesis technology resulting in one-step

Quantoom Biosciences S.A. (“Quantoom”), a biotech with the mission to improve access to essential medicines and autonomy in bioproduction through innovation, today announces that they have received grants from the

Univercells S.A. introduces its latest affiliate, Quantoom Biosciences S.A., a biotech with the mission to improve access to essential medicines and autonomy in bioproduction through innovation. Quantoom Biosciences develops clinically